Medivate Partners

Operator of an artificial intelligence and bioinformatics company designed to provide personalized drug treatment to everyone regardless of age, race or gender. The company provides genome information that allows patients with personalized drug reaction risk information, enabling doctors to reduce adverse drug reactions among patients.

Artiva Biotherapeutics, Inc., a biotech company, develops and manufactures cellular immunotherapies for cancer patients. The company offers a pipeline of off-the-shelf, allogeneic natural killer (NK) cell therapies for the treatment of hematologic cancers or solid tumors. The company’s products target CD20 and CD19 in B-cell lymphomas and HER2 in various solid tumors. The company was founded in 2019 and is headquartered in San Diego, California. Artiva Biotherapeutics, Inc. operates as a subsidiary of Green Cross Holdings Corporation.

Cognate Bioservices is a fully-integrated contract bioservices organization providing the highest level of scientific and management expertise. Cognate provides full development and cGMP manufacturing services to companies and institutions engaged in the development of cell-based products. The combination of highly experienced staff, successful track records and cGMP facilities makes Cognate one of the most qualified contract manufacturers of cell-based products in the world today.

WindMIL Therapeutics, Inc. is a biotechnology company focused on developing innovative cell therapies for cancer patients, utilizing insights from bone marrow immunology. Established in 2015 and based in Princeton, New Jersey, the company specializes in a novel class of therapies known as Marrow Infiltrating Lymphocytes (MILs). These therapies are derived from memory T cells found in the bone marrow and involve reactivating dormant T-cells to create effective immunotherapies. By harnessing the unique immunologic properties of bone marrow, WindMIL Therapeutics aims to provide life-saving treatment options for individuals battling cancer.

Cognate Bioservices is a fully-integrated contract bioservices organization providing the highest level of scientific and management expertise. Cognate provides full development and cGMP manufacturing services to companies and institutions engaged in the development of cell-based products. The combination of highly experienced staff, successful track records and cGMP facilities makes Cognate one of the most qualified contract manufacturers of cell-based products in the world today.

SillaJen, Inc., a biotechnology company, develops and commercializes oncolytic immunotherapy products. Its lead product is Pexa-Vec, which is in Phase III clinical trial for the treatment of advanced liver cancer. The company also develops JX-929 for the treatment of breast, colorectal, and pancreatic cancers; JX-970 for the treatment of tumor tissues; and JX-900 is a series of modified vaccinia vaccine. It has a cooperative research and development agreement with the National Cancer Institute for the development of a combination therapy for colorectal cancer. The company was founded in 2006 and is headquartered in Busan, South Korea.